Details of the Drug

General Information of Drug (ID: DMX0DUH)

Drug Name

MEDI2228

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody drug conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.
2	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.